Reported Earlier, Viridian Therapeutics Prices $225M Upsized Public Offering 10,666,600 Common Shares At $18.75/Share And Preferred Stock
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics has announced a $225 million upsized public offering, selling 10,666,600 common shares at $18.75 each and 20,000 Series B non-voting convertible preferred shares at $1,250.06250 each. The preferred shares can convert into 1,333,400 common shares. Underwriters have a 30-day option to purchase an additional 1,800,000 common shares.
September 12, 2024 | 6:53 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Viridian Therapeutics is conducting a $225M upsized public offering, which includes common and preferred shares. This could lead to short-term stock price fluctuations due to increased share supply.
The public offering increases the supply of shares, which can lead to a decrease in stock price due to dilution. The offering's size and the option for underwriters to purchase additional shares further contribute to potential downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100